# A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

> **NCT04172831** · PHASE3 · COMPLETED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 503 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** TNX-102 SL
- **DRUG:** Placebo SL Tablet

## Key facts

- **NCT ID:** NCT04172831
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-09
- **Primary completion:** 2020-10-29
- **Final completion:** 2020-10-29
- **Target enrollment:** 503 (ACTUAL)
- **Last updated:** 2022-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04172831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04172831, "A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04172831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*